Allogeneic haematopoietic stem cell transplantation is still the only available curative option for Familial Haemophagocytic Lymphohistiocytosis (FHLH). Most studies report outcomes after bone marrow or peripheral blood stem cell transplantation. We analysed the outcomes of 118 children with FHLH undergoing single-unit umbilical cord blood transplantation performed from 1996 to 2014. Myeloablative conditioning regimen was given to 90% of the patients, and was mostly busulfan-based (n = 81, 76%), including anti-thymocyte globulin or alemtuzumab (n = 102, 86%). The cumulative incidence of Day 60 neutrophil engraftment was 85%; and that of non-relapse mortality and acute graft-versus-host disease (GvHD) was 21% and 33% at 100 days, respectively. The 6-year cumulative incidence of chronic GvHD was 17% and the 6-year probability of overall survival was 55%. In multivariate analysis, children receiving a graft with a total nucleated cell dose greater than 9Á9 9 10 7 /kg had a better overall survival (hazard ratio [HR]: 0Á49, 95% CI: 0Á27-0Á88, P = 0Á02). Degree of human leucocyte antigen (HLA) matching was associated with improved disease-free survival (5/6 vs. 6/6 HR: 2Á11, 95% confidence interval [CI]: 1Á01-4Á4, P = 0Á05 and ≤4/6 vs. 6/6, HR: 2Á82, CI: 1Á27-6Á23, P = 0Á01). Umbilical cord blood transplantation with a high cell dose and good HLA match is a suitable alternative option to haematopoietic stem cell transplantation in children with FHLH who lack a HLA-matched donor.
Familial haemophagocytic lymphohistiocytosis (FHLH) is a systemic hyperinflammatory syndrome caused by excessive activation of lymphocytes and macrophages that produce high levels of cytokines as a result of genetic defects affecting the granule-mediated cytotoxicity pathway (Janka, 2007; Jordan et al, 2011; Janka & Lehmberg, 2013) . Primary haemophagocytic lymphohistiocytosis (HLH) consists of autosomal recessive genetic defects involving mutations in genes encoding PRF1 (Stepp et al, 1999) , UNC13D (Feldmann et al, 2003) , STXBP2 (Cote et al, 2009 ) and STX11 (zur Stadt et al, 2005) , or associated with primary immunodeficiencies, such as X-linked lymphoproliferative disease 1 and 2 (Arico et al, 2001) , Chediak-Higashi (Ward et al, 2002) and Griscelli syndrome (Bizario et al, 2004) . Secondary HLH is defined by absence of family history and unknown genetic defects and is usually triggered by infections, autoimmunity or malignancies. The diagnosis of HLH is made by clinical and laboratorial criteria, including fever, splenomegaly, cytopenia, hypertriglyceridaemia, hypofibrinogenaemia, haemophagocytosis, increased soluble interleukin-2 receptor alpha-chain and absent or markedly reduced natural killer cell function and no evidence of malignancy; mutations in genes known to cause HLH support the confirmation of diagnosis (Henter et al, 2007) .
The mortality associated with the disease is high if untreated and, to date, the only available definitively curative approach is haematopoietic stem cell transplantation (HSCT) (Henter et al, 2002; Horne et al, 2005) . The majority of the studies analysing the outcomes of HSCT in patients affected by FHLH have mainly considered children receiving either BM or peripheral blood as stem cell source, reporting overall survival (OS) between 44% and 100% (Horne et al, 2005; OuacheeChardin et al, 2006; Baker et al, 2008; Messina et al, 2018) .
Given that delaying HSCT may compromise disease control and thereby negatively influence clinical outcome, it is important that a suitable alternative source of stem cell be promptly available to reduce morbidity and mortality in these patients.
Studies of risk factors and outcomes of HSCT using umbilical cord blood as the cell source are scarce, with reported survival rates ranging from 25% to 85% (Ohga et al, 2010; Sawada et al, 2013; Patel et al, 2017) .
Methods
We retrospectively analysed 118 patients with the diagnosis of FHLH who underwent single-unit UCBT, as first HSCT, in European Society for Blood and Marrow Transplantation (EBMT) centres between 1996 and 2014.
The diagnosis of FHLH was established by either the presence of a genetic defect (PRF1, UNC13D, STXBP2, STX11), or the fulfilment of at least 5 of the 8 criteria defined by the Histiocyte Society (Henter et al, 1997) , positive family history and/or affected by treatment-resistant disease or experiencing relapsing episodes of haemophagocytosis. Patients with other primary immunodeficiency syndromes, such as Griscelli syndrome, Chediak Higashi or X-linked lymphoproliferative disease, were not included.
All patients received either a myeloablative conditioning (MAC) combined or not with thiotepa. Most of the MAC regimens were busulfan-(n = 81, 76%) or treosulfan-based (n = 21, 20%). The reduced intensity conditioning (RIC) used in this cohort of patients consisted of fludarabine and melphalan. Human leucocyte antigen (HLA) matching was defined at the antigen level for A and B loci and at the allele level for the DRB1 locus.
The primary endpoint was OS, defined as time from UCBT to death from any cause or last follow-up, whichever came first; surviving patients were censored at last follow-up. Secondary endpoints were neutrophil engraftment, acute and chronic graft-versus-host disease (GvHD), non-relapse mortality (NRM), relapse incidence (RI) and disease-free survival (DFS).
Neutrophil engraftment was defined as a neutrophil count ≥0Á5 9 10 9 /l for 3 consecutive days, without evidence of either autologous reconstitution or graft rejection within the first 100 days. Acute and chronic GvHD were assessed according to standard criteria (Glucksberg et al, 1974; Filipovich et al, 2005) . NRM was defined as time to death of any cause not related to relapse and RI was calculated by analysing the time from UCBT to relapse. DFS was defined as time from UCBT to relapse, death from any cause or last follow-up, whichever came first. Variables that reached a P value <0Á10 in univariate analysis (namely, number of HLA mismatches, dose of total nucleated cells [TNC] infused) or were clinically relevant (year of UCBT, disease status at UCBT) were included in the multivariate models. P-values were two sided and type I error was settled at 0Á05. Confidence intervals were estimated at 95%. Analyses were performed with SPSS (IBM SPSS Statistics for Windows, Version 19.0; IBM Corp, Armonk, NY, USA) and R (R Foundation for Statistical Computing, Version 3.2.3; Vienna, Austria) software packages. Multivariate analyses were performed only for OS and DFS because of the low number of events reported for other outcomes. Parents or legal guardians gave informed consent for data sharing for research. Eurocord and the Inborn Errors Working Party of the EBMT approved this study.
Results
Patient and disease characteristics are summarized in Table I . Fifty-two percent of patients were male (n = 61) and 72 (62%) had a positive cytomegalovirus serology. The median age at UCBT was 1 year (0Á1-14). The median age at diagnosis was 0Á3 (0-14) years, with 19 (16%) patients diagnosed at birth due to family history. A family history of HLH was reported in 44 (37%) patients and consanguinity in 41 (35%). Molecular genetic studies for FHLH genes were available for 75 (64%) patients: 28 (24%) had PRF1 mutation, 23 (20%) had UNC13D defect, 19 (16%) had STXBP2 mutation, 4 (3%) had STX11 mutation and one patient (1%) had combined PRF1 and STX11 defects. Twenty (17%) patients had a family history of HLH and the diagnosis was based on clinical features for the remaining 23 patients (19%). Neurological involvement was present at diagnosis in 66 (57%) patients. Before UCBT, most patients had been treated according to the HLH 2004 protocol (Henter et al, 2007) , including etoposide and ciclosporin A (CsA) (n = 75, 64%). The majority of patients (n = 68, 60%) were in complete remission (CR) at the time of UCBT.
Transplant characteristics are provided in Table II . Briefly, median time from diagnosis to UCBT was 5Á3 (0-57) months. Ninety percent of patients received MAC regimens, mostly busulfan-based (n = 81, 76%). Etoposide was included in 38% of MAC regimens. Most conditioning regimens (n = 102, 86%) included either anti-thymocyte globulin (ATG) or alemtuzumab. The most used GvHD prophylaxis was CsA combined with prednisone (n = 57, 48%). The median dose of TNC at infusion was 9Á9 9 10 7 / kg. HLA donor-recipient matching was 6/6 in 35 (30%), 5/6 in 56 (48%) and ≤4/6 in 25 (22%) patients.
Engraftment and GvHD
The cumulative incidence of Day 60 neutrophil engraftment was 85% (95% confidence interval [CI]: 78-92%) and the median time of neutrophil engraftment was 19 (range: 9-54) days. Of the 18 patients (15%) who failed to achieve neutrophil engraftment, 15 died within a median time of 2Á8 months after UCBT and three were alive (two after receiving a new transplant) at the last follow-up. Chimerism studies were available for 88 of the 100 patients who engrafted for neutrophils: 79 had full donor chimerism and 9 had mixed chimerism at 100 days after UCBT. Thirty-nine children experienced grade II-IV acute GvHD at a median time of 20 (range 5-101) days after UCBT. The cumulative incidence of Day 100 grade II-IV acute GvHD was 33% (95% CI: 26-43%).
The cumulative incidence of chronic GvHD was 17% (95% CI 11-26%) at 6 years, with a median time of onset of 123 (range 95-715) days. Among the 18 patients who experienced chronic GvHD, 7 had the extensive form of the disease.
Non-relapse mortality and relapse incidence
Overall, 52 children died. The cumulative incidence of NRM was 21% (95% CI: 15-30%) at 100 days and 36% (95% CI: 28-46%) at 6 years. The primary cause of death was relapse in 10 (20%) patients and transplant-related causes in 40 (78%), namely infections, n = 10; GvHD, n = 8; acute respiratory distress syndrome, n = 4; idiopathic pneumonia syndrome, n = 2; veno-occlusive disease, n = 2; haemorrhage, n = 2; post-transplant lymphoproliferative disorder, n = 1; other causes, n = 11 (including 5 patients with missing information). The cumulative incidence of relapse at 6 years was 14% (95% CI: 9-22%). Sixteen patients relapsed, but information about relapse site was available for only 8 of them (systemic n = 5, central nervous system [CNS] n = 2, both systemic and CNS n = 1). Chimerism at last follow-up was available for 7/ 16 patients who relapsed: 3 patients had full donor engraftment and relapsed at 6 days, 7 and 50 months post-transplant, 1 patient had mixed chimerism and 3 had autologous reconstitution.
Overall survival and disease-free survival
The median follow-up for survivors was 75 (range: 3Á3-211) months. The probability of OS was 55% (95% CI: 45-64%) at 6 years ( Fig 1A) . In univariate analysis, children infused with more than 9Á9 9 10 7 /kg TNC had a better OS (65% vs. 42%, P = 0Á04) (Fig 1B) . The 6-year probability of DFS was 50% (95% CI: 40-60%) (Fig 2A) . According to HLA match, DFS was 69% for 6/6, 49% for 5/6 and 34% for ≤4/ 6 matched UCBT (P = 0Á06) (Fig 2B) . We also did not observe an impact of neurological involvement of FHLH at diagnosis on OS and DFS. 0Á46, 95% CI 0Á24-0Á87, P = 0Á02). Higher degree of HLA mismatch was associated with worse DFS (5/6 vs. 6/6: HR 2Á09, 95% CI 1Á01-4Á4, P = 0Á05 and ≤4/6 vs. 6/6: 2Á86, 95% CI 1Á26-6Á50, P = 0Á01). We did not observe an impact of disease status or age at the time of UCBT on OS and DFS.
Discussion
We report the outcomes of the largest cohort of paediatric patients who underwent UCBT for FHLH thanks to an international collaboration promoted by Eurocord and the Inborn Errors Working Party of EBMT. We found that UCBT with a well HLA-matched cord blood unit (6/6 or 5/6) and a higher cell dose was a suitable transplant option for children who lack a HLA-matched donor, with an OS of 55% for the whole cohort of patients analysed and DFS of 69% for 6/6 HLA-matched unit of umbilical cord blood. Previous studies assessing the outcomes of HSCT in patients affected by FHLH have mainly considered children receiving either bone marrow or peripheral blood as stem cell source (Henter et al, 2002; Horne et al, 2005; OuacheeChardin et al, 2006) . The OS reported in the majority of these studies varies between 44% (58% in mostly haploidentical transplants) to 71% (Horne et al, 2005; Ouachee-Chardin et al, 2006; Cesaro et al, 2008) .
Studies using UCBT for patients affected by FHLH are scarce and the results are variable, showing survival rates ranging from 25% to 85% (Cesaro et al, 2008; Ohga et al, 2010; Yoon et al, 2010; Nishi et al, 2012; Shimizu et al, 2012; Patel et al, 2017) . Ohga et al (2010) reported an OS of 65% in patients undergoing UCBT (n = 28) for familial and Epstein-Barr virus-driven HLH. More recently Patel et al (2017) also reported a long-term OS of 71Á4% in 14 patients undergoing UCBT in a single centre. In our study, we observed a lower 6-year probability of OS of 55%, but in a larger cohort of patients.
The main causes of treatment failure in previous studies using UCBT (Baker et al, 2008; Cesaro et al, 2008; Ohga et al, 2010; Yoon et al, 2010; Nishi et al, 2012; Trottestam et al, 2012; Sawada et al, 2013; Patel et al, 2017) included relatively high rates of engraftment failure (between 9 and 22%) (Horne et al, 2005; Ouachee-Chardin et al, 2006; Baker et al, 2008) and NRM, mostly in the first 100 days following UCBT (Nishi et al, 2012; Sawada et al, 2013; Nikiforow, 2015; Seo, 2015) .
In our series, we observed a cumulative incidence of neutrophil engraftment of 85%, with 90% of patients achieving full donor chimerism at 100 days following UCBT.
Amongst the 18 patients who failed to engraft, 4 had active disease and 1 received RIC but also had active disease at transplantation, and all of them received a TNC dose of more than 4 9 10 7 /kg.
NRM has been previously reported to be the main cause of death following HSCT for FLHL with high incidence of veno-occlusive disease and lung toxicity, mostly associated with myeloablative conditioning (Cesaro et al, 2008; Ohga et al, 2010; Nishi et al, 2012; Patel et al, 2017) . Previous research attempted to assess optimal conditioning regimens in UCBT and to compare the outcomes between bone marrow graft and cord blood transplants using MAC and RIC (Cooper et al, 2008) . Sawada et al (2013) reported no differences in OS between MAC and RIC regimens (63% vs. 62%, respectively), and better engraftment rates when using ATG and higher dose of melphalan (>120 mg/m 2 ). Patel et al (2017) also added hydroxycarbamide and thiotepa to fludarabine, melphalan and alemtuzumab with 3/4 patients achieving full donor chimerism and good immune reconstitution. Although the number of patients receiving RIC in our cohort was too small to draw definitive conclusions (n = 12), it is interesting to note that the majority of these patients achieved neutrophil engraftment (n = 11) and full donor chimerism (n = 10) and only 1 experienced relapse after UCBT. We did not have enough data on lineage-specific chimerism to be able to correlate it with outcomes in patients with mixed chimerism. Baker et al (2008) showed a significant impact of disease status at the time of UCBT on outcomes with 20% OS in patients transplanted with active disease using bone marrow, peripheral blood or umbilical cord blood as the cell source compared to 49% OS in patients in complete remission, a finding also confirmed in other studies (Horne et al, 2005; Ouachee-Chardin et al, 2006) . Interestingly, we did not observe an impact of disease status at the time of transplantation on survival or engraftment rates. The small number of patients transplanted with active disease in our cohort prevented us to reach conclusions with statistical significance.
In conclusion, we identified one main risk factor associated with OS and one main risk factor associated with DFS following UCBT in patients affected by FHLH: TNC dose and choice of a well-matched (6/6 or 5/6) cord blood unit, respectively. Patients who received TNC cell dose higher than 9Á9 9 10 7 /kg had an OS of 65% vs. 42% for patients receiving a dose lower than 9Á9 9 10 7 /kg. There was a trend to better DFS according to HLA match, with DFS of 69% for 6/6, 49% for 5/6 and 34% for ≤4/6 matched UCBT, respectively (P = 0Á06). These results are comparable with previous observations from the Eurocord group reporting better outcomes in patients with non-malignant conditions receiving cell doses higher than 4-5 9 10 7 /kg and a well-matched graft (Rocha & Gluckman, 2009 ). Investigations regarding optimal conditioning for patients affected by FHLH to promote stable engraftment and to reduce toxicity are still warranted. A possible alternative to overcome the risk of transplant-related mortality and to ensure adequate engraftment rates in patients undergoing UCBT may be to individualize ATG exposure using therapeutic drug monitoring (Admiraal et al, 2015) .
It would also be important to compare alternative modalities of HSCT, such as UCBT and alpha/beta T-cell depletion or high dose cyclophosphamide post-transplantation haploidentical approaches.
